{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:24:18Z","timestamp":1787682258713,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ajo.2019.09.019","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T01:51:46Z","timestamp":1569376306000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-9886","authenticated-orcid":false,"given":"Supanut","family":"Apinyawasisuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Chongpison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawin","family":"Thitisaksakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supharat","family":"Jariyakosol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2019.09.019_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/ICU.0b013e328358b94a","article-title":"Ocular myasthenia gravis","volume":"23","author":"Vaphiades","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.09.019_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","article-title":"Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification","volume":"36","author":"Wong","year":"2016","journal-title":"J Neuroophthalmol"},{"issue":"1-2","key":"10.1016\/j.ajo.2019.09.019_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","article-title":"Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients","volume":"273","author":"Hong","year":"2008","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.ajo.2019.09.019_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"Mazzoli","year":"2018","journal-title":"Int J Neurosci"},{"issue":"1","key":"10.1016\/j.ajo.2019.09.019_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.ajo.2019.09.019_bib6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ajo.2019.09.019_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-1331.2012.03843.x","article-title":"Smoking and socio-economic status may affect myasthenia gravis","volume":"20","author":"Maniaol","year":"2013","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.ajo.2019.09.019_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/WNO.0000000000000306","article-title":"Cigarette smoking and activities of daily living in ocular myasthenia gravis","volume":"36","author":"Gratton","year":"2016","journal-title":"J Neuroophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2019.09.019_bib9","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","article-title":"Generalization after ocular onset in myasthenia gravis: a case series in Germany","volume":"265","author":"Li","year":"2018","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.ajo.2019.09.019_bib10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/mus.25983","article-title":"Low conversion rate of ocular to generalized myasthenia gravis in Singapore","volume":"57","author":"Teo","year":"2018","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ajo.2019.09.019_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ajo.2019.09.019_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ajo.2019.09.019_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.25971","article-title":"Ocular presentation of myasthenia gravis: a natural history cohort","volume":"57","author":"Kamarajah","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.ajo.2019.09.019_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2019.09.019_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves\u2019 disease","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ajo.2019.09.019_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/IIO.0000000000000277","article-title":"Thyroid eye disease and myasthenia gravis","volume":"59","author":"Bojikian","year":"2019","journal-title":"Int Ophthalmol Clin"},{"issue":"8941","key":"10.1016\/j.ajo.2019.09.019_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(95)91185-5","article-title":"Nicotine-sensitive myasthenia gravis","volume":"345","author":"Moreau","year":"1995","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajo.2019.09.019_bib18","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.3390\/ijms15069809","article-title":"Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity","volume":"15","author":"Pohanka","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ajo.2019.09.019_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.ajo.2019.09.019_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<543::AID-MUS2>3.0.CO;2-9","article-title":"Cytokines and the pathogenesis of myasthenia gravis","volume":"20","author":"Zhang","year":"1997","journal-title":"Muscle Nerve"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419304775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419304775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:41:05Z","timestamp":1757598065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419304775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":20,"alternative-id":["S0002939419304775"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2019.09.019","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2019.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}